Testicular dose contributed by X-ray volume image-(XVI)-guided intensity-modulated radiotherapy (IMRT) in prostate cancer patients

Q4 Medicine

Nowotwory Pub Date : 2020-01-01 DOI:10.5603/NJO.2020.0012

D. Hempel, R. Chrenowicz, T. Filipowski, M. Wojtukiewicz, E. Sierko

{"title":"Testicular dose contributed by X-ray volume image-(XVI)-guided intensity-modulated radiotherapy (IMRT) in prostate cancer patients","authors":"D. Hempel, R. Chrenowicz, T. Filipowski, M. Wojtukiewicz, E. Sierko","doi":"10.5603/NJO.2020.0012","DOIUrl":null,"url":null,"abstract":"Introduction: To assess the dose received by testes during XVI-guided IMRT in prostate cancer patients (PCPs). Material and methods: Testes dose was calculated in 56 PCPs who underwent definitive IMRT using 6 MV or 15 MV photon energies. The dose was measured by thermoluminescent dosimeters (TLDs) MTS-N attached to the scrotum during the first three fractions of IMRT. Testicular concomitant exposure from XVI was measured using a PTW DIADOS E diagnostic dosimeter in ten randomly chosen patients. Results: The mean and standard deviation values of the average calculated testes dose was 123 ± 117 cGy comprising 1.6% of the prescribed total irradiation dose (Dt). A testicular dose measured by TLDs was 303 ± 110.5 cGy (4% of Dt) and depended on the distance from isocenter to testes (r = –0.8). From one XVI scan, the detected testicular mean dose was 4.3 mGy. Mean XVI scan numbers for all patients was 10.4 so mean concomitant dose in testes was 44.7 mGy (0.06% of Dt). Conclusions: Testicular dose may be significant in the aspect of fertility during IMRT in PCPs. Kilovoltage XVI-contributed dose to testes seems to be clinically negligible.","PeriodicalId":39938,"journal":{"name":"Nowotwory","volume":"18 1","pages":"47-53"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nowotwory","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/NJO.2020.0012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: To assess the dose received by testes during XVI-guided IMRT in prostate cancer patients (PCPs). Material and methods: Testes dose was calculated in 56 PCPs who underwent definitive IMRT using 6 MV or 15 MV photon energies. The dose was measured by thermoluminescent dosimeters (TLDs) MTS-N attached to the scrotum during the first three fractions of IMRT. Testicular concomitant exposure from XVI was measured using a PTW DIADOS E diagnostic dosimeter in ten randomly chosen patients. Results: The mean and standard deviation values of the average calculated testes dose was 123 ± 117 cGy comprising 1.6% of the prescribed total irradiation dose (Dt). A testicular dose measured by TLDs was 303 ± 110.5 cGy (4% of Dt) and depended on the distance from isocenter to testes (r = –0.8). From one XVI scan, the detected testicular mean dose was 4.3 mGy. Mean XVI scan numbers for all patients was 10.4 so mean concomitant dose in testes was 44.7 mGy (0.06% of Dt). Conclusions: Testicular dose may be significant in the aspect of fertility during IMRT in PCPs. Kilovoltage XVI-contributed dose to testes seems to be clinically negligible.

查看原文本刊更多论文

前列腺癌患者x射线体积成像(XVI)引导的调强放疗(IMRT)对睾丸剂量的贡献

目的:评估前列腺癌患者(pcp)在xvi引导下IMRT期间睾丸接受的剂量。材料和方法:使用6 MV或15 MV光子能量计算56例接受确定IMRT的pcp的睾丸剂量。在IMRT的前三个部分，通过附着在阴囊上的热释光剂量计(tld) MTS-N测量剂量。在随机选择的10例患者中，使用PTW DIADOS E诊断剂量计测量XVI的睾丸伴随照射。结果:计算睾丸平均剂量的平均值和标准差为123±117 cGy，占规定总辐照剂量(Dt)的1.6%。tld测量的睾丸剂量为303±110.5 cGy (4% Dt)，与等中心到睾丸的距离有关(r = -0.8)。从一次XVI扫描中，检测到的睾丸平均剂量为4.3 mGy。所有患者的平均XVI扫描次数为10.4次，睾丸的平均伴随剂量为44.7 mGy(0.06%的Dt)。结论:睾丸剂量可能对pcp患者在IMRT期间的生育能力有重要影响。kv xvi对睾丸的贡献剂量在临床上似乎可以忽略不计。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nowotwory Medicine-Oncology

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： NOWOTWORY Journal of Oncology publishes papers which cover all aspects of oncology but concentrates on clinical studies, both research orientated and treatment orientated, rather than on laboratory studies. Contributions are also welcomed from the fields of epidemiology, tumor pathology, radiobiology and radiation physics.